Sulfoglycodendrimer Therapeutics for HIV‐1 and SARS‐CoV‐2 is a research paper published in Advanced Therapeutics (2021). On theSindex it has a DataRank of 0. It has been cited 10 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: P30 CA016058
NCATS NIH HHS
Grant: UL1 TR002003
NIAID NIH HHS
Grant: HHSN272201800004C
NIH HHS
Grant: S10 OD018507
NCRR NIH HHS
Grant: S10 RR025660
NIGMS NIH HHS
Grant: SC3 GM119521
National Institutes of Health
Grant: 5SC3GM119521-08
Glycopolymer Inhibitors of Heparan Sulfate Proteoglycan Binding Pathogens
National Institutes of Health
Grant: 3P30CA016058-15S1
CORE--HORMONE RECEPTOR LABORATORY
National Institutes of Health
Grant: 1S10RR025660-01A1
Acquisition of a MALDI-TOF/TOF MS for Glycomic and Lipidomic Research
National Institutes of Health
Grant: 1S10OD018507-01
15 Tesla Bruker solariX FTICR MS
FWCI
1.28
Citation Percentile
0.8%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals